229 related articles for article (PubMed ID: 20445271)
1. Preliminary X-ray crystallographic study of the receptor-binding domain of the D/C mosaic neurotoxin from Clostridium botulinum.
Nuemket N; Tanaka Y; Tsukamoto K; Tsuji T; Nakamura K; Kozaki S; Yao M; Tanaka I
Acta Crystallogr Sect F Struct Biol Cryst Commun; 2010 May; 66(Pt 5):608-10. PubMed ID: 20445271
[TBL] [Abstract][Full Text] [Related]
2. High-level expression, purification, crystallization and preliminary X-ray crystallographic studies of the receptor-binding domain of botulinum neurotoxin serotype D.
Zhang Y; Gao X; Qin L; Buchko GW; Robinson H; Varnum SM
Acta Crystallogr Sect F Struct Biol Cryst Commun; 2010 Dec; 66(Pt 12):1610-3. PubMed ID: 21139207
[TBL] [Abstract][Full Text] [Related]
3. Structural and mutational analyses of the receptor binding domain of botulinum D/C mosaic neurotoxin: insight into the ganglioside binding mechanism.
Nuemket N; Tanaka Y; Tsukamoto K; Tsuji T; Nakamura K; Kozaki S; Yao M; Tanaka I
Biochem Biophys Res Commun; 2011 Jul; 411(2):433-9. PubMed ID: 21749855
[TBL] [Abstract][Full Text] [Related]
4. Domain organization in Clostridium botulinum neurotoxin type E is unique: its implication in faster translocation.
Kumaran D; Eswaramoorthy S; Furey W; Navaza J; Sax M; Swaminathan S
J Mol Biol; 2009 Feb; 386(1):233-45. PubMed ID: 19118561
[TBL] [Abstract][Full Text] [Related]
5. Crystallographic evidence for doxorubicin binding to the receptor-binding site in Clostridium botulinum neurotoxin B.
Eswaramoorthy S; Kumaran D; Swaminathan S
Acta Crystallogr D Biol Crystallogr; 2001 Nov; 57(Pt 11):1743-6. PubMed ID: 11679763
[TBL] [Abstract][Full Text] [Related]
6. Unique ganglioside binding by botulinum neurotoxins C and D-SA.
Kroken AR; Karalewitz AP; Fu Z; Baldwin MR; Kim JJ; Barbieri JT
FEBS J; 2011 Dec; 278(23):4486-96. PubMed ID: 21554541
[TBL] [Abstract][Full Text] [Related]
7. Unique biological activity of botulinum D/C mosaic neurotoxin in murine species.
Nakamura K; Kohda T; Shibata Y; Tsukamoto K; Arimitsu H; Hayashi M; Mukamoto M; Sasakawa N; Kozaki S
Infect Immun; 2012 Aug; 80(8):2886-93. PubMed ID: 22665374
[TBL] [Abstract][Full Text] [Related]
8. Structural analysis of the catalytic and binding sites of Clostridium botulinum neurotoxin B.
Swaminathan S; Eswaramoorthy S
Nat Struct Biol; 2000 Aug; 7(8):693-9. PubMed ID: 10932256
[TBL] [Abstract][Full Text] [Related]
9. Binding of Clostridium botulinum type C and D neurotoxins to ganglioside and phospholipid. Novel insights into the receptor for clostridial neurotoxins.
Tsukamoto K; Kohda T; Mukamoto M; Takeuchi K; Ihara H; Saito M; Kozaki S
J Biol Chem; 2005 Oct; 280(42):35164-71. PubMed ID: 16115873
[TBL] [Abstract][Full Text] [Related]
10. Structural Analysis of Botulinum Neurotoxins Type B and E by Cryo-EM.
Košenina S; Martínez-Carranza M; Davies JR; Masuyer G; Stenmark P
Toxins (Basel); 2021 Dec; 14(1):. PubMed ID: 35050991
[TBL] [Abstract][Full Text] [Related]
11. High resolution crystal structures of Clostridium botulinum neurotoxin A3 and A4 binding domains.
Davies JR; Rees J; Liu SM; Acharya KR
J Struct Biol; 2018 May; 202(2):113-117. PubMed ID: 29288126
[TBL] [Abstract][Full Text] [Related]
12. Crystal structures of botulinum neurotoxin DC in complex with its protein receptors synaptotagmin I and II.
Berntsson RP; Peng L; Svensson LM; Dong M; Stenmark P
Structure; 2013 Sep; 21(9):1602-11. PubMed ID: 23932591
[TBL] [Abstract][Full Text] [Related]
13. Botulinum neurotoxin X lacks potency in mice and in human neurons.
Gregg BM; Matsumura T; Wentz TG; Tepp WH; Bradshaw M; Stenmark P; Johnson EA; Fujinaga Y; Pellett S
mBio; 2024 Mar; 15(3):e0310623. PubMed ID: 38347673
[TBL] [Abstract][Full Text] [Related]
14. Crystallization and preliminary crystallographic studies of the HA3 subcomponent of the type B botulinum neurotoxin complex.
Nishimura K; Kitadokoro K; Takegahara Y; Sugawara Y; Matsumura T; Karatani H; Fujinaga Y
Acta Crystallogr Sect F Struct Biol Cryst Commun; 2011 Oct; 67(Pt 10):1244-6. PubMed ID: 22102038
[TBL] [Abstract][Full Text] [Related]
15. Improved detection methods by genetic and immunological techniques for botulinum C/D and D/C mosaic neurotoxins.
Nakamura K; Kohda T; Seto Y; Mukamoto M; Kozaki S
Vet Microbiol; 2013 Mar; 162(2-4):881-890. PubMed ID: 23206412
[TBL] [Abstract][Full Text] [Related]
16. Exchange of the H(CC) domain mediating double receptor recognition improves the pharmacodynamic properties of botulinum neurotoxin.
Rummel A; Mahrhold S; Bigalke H; Binz T
FEBS J; 2011 Dec; 278(23):4506-15. PubMed ID: 21624052
[TBL] [Abstract][Full Text] [Related]
17. Botulinum neurotoxin B recognizes its protein receptor with high affinity and specificity.
Jin R; Rummel A; Binz T; Brunger AT
Nature; 2006 Dec; 444(7122):1092-5. PubMed ID: 17167421
[TBL] [Abstract][Full Text] [Related]
18. Identification of a unique ganglioside binding loop within botulinum neurotoxins C and D-SA .
Karalewitz AP; Kroken AR; Fu Z; Baldwin MR; Kim JJ; Barbieri JT
Biochemistry; 2010 Sep; 49(37):8117-26. PubMed ID: 20731382
[TBL] [Abstract][Full Text] [Related]
19. Enhancing toxin-based vaccines against botulism.
Przedpelski A; Tepp WH; Zuverink M; Johnson EA; Pellet S; Barbieri JT
Vaccine; 2018 Feb; 36(6):827-832. PubMed ID: 29307477
[TBL] [Abstract][Full Text] [Related]
20. Characterization of the functional activity of botulinum neurotoxin subtype B6.
Kohda T; Nakamura K; Hosomi K; Torii Y; Kozaki S; Mukamoto M
Microbiol Immunol; 2017 Nov; 61(11):482-489. PubMed ID: 28898517
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
